Modified recombinant human erythropoietin with potentially reduced immunogenicity

Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. However, some patients repeatedly receiving rHuEPO develop anti-rHuEPO neutralizing antibodies leading to the development of pure red...

Descripción completa

Detalles Bibliográficos
Autores principales: Susantad, Thanutsorn, Fuangthong, Mayuree, Tharakaraman, Kannan, Tit-oon, Phanthakarn, Ruchirawat, Mathuros, Sasisekharan, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810742/
https://www.ncbi.nlm.nih.gov/pubmed/33452310
http://dx.doi.org/10.1038/s41598-020-80402-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810742/
https://www.ncbi.nlm.nih.gov/pubmed/33452310
http://dx.doi.org/10.1038/s41598-020-80402-1

Ejemplares similares